Posted: 04/28/2025 04:00 am
Sera Prognostics, a notable player in the field of maternal and neonatal health through its pioneering pregnancy biomarker technologies, has captured attention not just for its advancements in prenatal care but also for its notable executive compensation packages. As the company navigates financial avenues, including public offerings and earnings reports, an analysis of its executive compensation offers insight into company dynamics and priorities.
For the fiscal year 2024, Paul Kearney, Ph.D., Chief Data Officer at Sera Prognostics, received a total compensation of $847,042. This package included a base salary of $391,340, stock awards totaling $378,308, incentive plan compensation of $63,594, and an additional $13,800 categorized under 'all other compensation’^1. The significant portion attributed to stock awards underscores the company's strategy of aligning executive interests with shareholder value, a common practice among growth-focused companies.
In comparison, John J. Boniface, Ph.D., Chief Scientific Officer, had a total compensation of $826,246 for 2022, with a notable option award component of $280,787 alongside a base salary of $406,100. This reflects an emphasis on long-term incentives reflecting the value of innovation and scientific leadership crucial to Sera's business model^2. Meanwhile, Jay Moyes, in his role as Chief Financial Officer in 2021, received $945,891 in total compensation, of which $398,591 was granted as an option award, reflecting the company's focus on financial stewardship^3.
Navigating these individual compensation structures amid larger financial developments, Sera recently announced a $50 million public offering intended to bolster its financial positioning and drive strategic initiatives^4. The offering was part of an ongoing strategy to strengthen its market position, as also seen in their participation at high-profile healthcare conferences^5.
However, not all is rosy; Sera's financial results have shown challenges. Its Q4 2024 earnings reported a loss of $0.25 per share, slightly missing the Zacks Consensus Estimate^6. Despite these setbacks, the company's stock price, although currently trading at $3.165, reflects fluctuations reflective of market confidence amidst broader industry trends^7.
In the backdrop of these financial ebbs and flows, the executive compensation narrative at Sera Prognostics is critically tied to its growth story. These packages reflect an emphasis on retaining key talent to navigate the complex healthcare landscape, innovate continuously, and ultimately improve maternal and neonatal health outcomes.
:
1. Source: 2024 Executive Compensation for Sera Prognostics, SEC Filing [Link](https://www.sec.gov/Archives/edgar/data/1534969/000095017025057359/0000950170-25-057359-index.htm).
2. Source: 2022 Executive Compensation for Sera Prognostics, SEC Filing [Link](https://www.sec.gov/Archives/edgar/data/1534969/000153496924000077/0001534969-24-000077-index.htm).
3. Source: 2021 Executive Compensation for Sera Prognostics, SEC Filing [Link](https://www.sec.gov/Archives/edgar/data/1534969/000153496923000043/0001534969-23-000043-index.htm).
4. Source: Sera Prognostics Announces Pricing of $50 Million Public Offering, PRNewswire [Link](https://www.prnewswire.com/news-releases/sera-prognostics-announces-pricing-of-50-million-public-offering-302372994.html).
5. Source: Sera Prognostics to Present at TD Cowen 45th Annual Health Care Conference, PRNewswire [Link](https://www.prnewswire.com/news-releases/sera-prognostics-announces-appointment-of-jeff-elliott-to-its-board-ryan-trimble-and-marcus-wilson-to-step-down-302406272.html).
6. Source: Sera Prognostics (SERA) Reports Q4 Loss, Misses Revenue Estimates, Zacks [Link](https://www.zacks.com/stock/news/2432398/sera-prognostics-inc-sera-reports-q4-loss-misses-revenue-estimates).
7. Source: Current Stock Price Snapshot for Sera Prognostics, Financial Market Data.
